The authors performed an interesting exercise to create a evidence map of pancreatic surgery which will be updated permanently.
I have several questions which l have listed in their order in the manuscript as minor (typos, style) or major (potential bias, major concern): 1.Abstract, methods: was PubMed or MEDLINE used?(minor) 2.Methods, study selection: are only systematic reviews used that include all trials? (minor) 3.Methods, study selection: often, more systematic reviews are present than randomized controlled trials. Are all these systematic reviews included? How to choose?(minor) 4.Methods, study selection: if an individual-patient-meta-analysis (IPDMA) of the randomized controlled trials is available is this then also used? And ranked above the 'tranditional' systematic reviews?(minor) 5.Methods: why are studies on adjuvant/neoadjuvant treatment excluded? These are arbitrarily amongst the most relevant in pancreatic (cancer) surgery?(major) 6.Methods: why use grade A complications? Would suggest only B/C.(minor) 7.General remark: only during the reading of the manuscript it becomes fully clear that this the actual map has not been created yet. Would emphasize this better in abstract/introduction.(minor) 8.Methods: would provide time frames in more detail. For instance on when the first version is expected and when updates (how many times per year) will be done. Finally, it may be realistic to present this work for the coming x (say, 5?) years. As it stands now, it is an non-ending "pledge" to update this website. It may be reasonable to reflect after a certain number of years.(major)
REVIEWER
Chris Please can the authors provide clarification on the study selection process? For example, how will any conflicts/disagreements between the independent reviewers be resolved? Will you be using any specialised software to carry out the screening?
Are the 'minimal requirements' for an SR you set out based on any established quality criteria for an SR (e.g. ROBIS)?
I think it would be useful for clarity to see a PICO table that clearly lists the inclusion and exclusion criteria for the review, which can sit alongside the narrative summary of eligibility criteria. Further, I found the last couple of sentences (see Page 8) in relation to eligible interventions slightly convoluted.
Are you formally critially apparising the included SRs as well as the RCTs?
Regarding the data extraction, you mention a pre-defined spreadsheet earlier in the protocol but then later on talk about a database 'tailored for this project' will be used to 'save resources during data extraction'. Are you extracting straight into this database or are you going to use the spreadsheet and then translate data into this database later? Please clarify.
VERSION 1 -AUTHOR RESPONSE
Reviewer #1: Marc Besselink, University of Amsterdam, the Netherlands Question 1.1: Abstract, methods: was PubMed or MEDLINE used? (minor) Answer 1.1: Thank you for asking for clarification. We searched MEDLINE via PubMed and we corrected this throughout the manuscript.
Question 1.2: Methods, study selection: are only systematic reviews used that include all trials? (minor) Answer 1.2: We will include all systematic reviews on a research topic irrespective of the trials included. The main goal of inclusion of systematic reviews is to detect research topics without existing RCT to consequently direct the attention of researchers towards this topic in order to fill the evidence gap. Please see also answer 1.3. Question 1.3: Methods, study selection: often, more systematic reviews are present than randomized controlled trials. Are all these systematic reviews included? How to choose? (minor) Answer 1.3: This is a very important remark. Regarding the selection of systematic reviews we only applied minimum quality requirements (systematic reviews searching two databases and performing a critical appraisal with a validated tool). As mentioned above the only purpose of the systematic reviews within this project is to discover research topics, which are not covered by evidence deriving from RCT. However, for reasons of completeness and not to patronise the readers of the evidence map we will show all existing systematic reviews with their original conclusion.
Under "Data synthesis for creation of the evidence map" it now states more clearly: "Information on existing SR will be shown within the evidence map and will be used for identification of evidence gaps in the research topics i.e. missing RCT. Therefore, no quantitative data will be extracted and no critical appraisal of SR will be performed. Including SR in the evidence map is preferred to the inclusion of all other primary study types like non-randomised prospective trials or retrospective studies."
Question 1.4: Methods, study selection: if an individual-patient-meta-analysis (IPDMA) of the randomized controlled trials is available is this then also used? And ranked above the 'traditional' systematic reviews? (minor) Answer 1.4: IPDMA will certainly change the face of existing evidence over the next decade and we agree that they are of higher value then the traditional meta-analyses. At the moment it is not planned to discriminate between traditional and IPD meta-analyses. However, they will be included like all other meta-analyses within the map. For the future development of the map it is possible that we will give a special attention to this kind of meta-analyses or that we even try to gather the individual patient data from the included RCT. We hope for your understanding that such a large project has to be built step by step and some limitations have to be made at the moment.
Question 1.5: Methods, why are studies on adjuvant/neoadjuvant treatment excluded? These are arbitrarily amongst the most relevant in pancreatic (cancer) surgery? (major) Answer 1.5: We completely agree that the existing RCT of systemic treatment of pancreatic cancer are landmark trials. During the initiation phase of this project we had long discussions on the focus of the current evidence map and we decided to focus on pancreatic surgery. If we would open also to systemic therapy a clear limitation would be impossible. Then also evidence on palliative systemic therapy, targeted therapy, best supportive care etc. would have to be integrated. We came to the decision that this would generate an evidence map of "pancreatic cancer" on its own. Furthermore, we also think that only including the neoadjuvant trials (which would have an impact on the surgical part) would not be adequate without the rest of systematic therapy.
In summary, as this project will be an evidence map on pancreatic surgery and not on pancreatic cancer specifically, we decided to include only trials with interventions directly surrounding the perioperative period. However, as we plan to expand this project step-by-step a map of pancreatic cancer will certainly be created, but not within this pilot project.
Question 1.6: Methods, why use grade A complications? Would suggest only B/C. (minor) Answer 1.6: Thank you for pointing out this important surgical issue. We will extract data on A, B and C complications according to the ISGPS definitions. However, within the meta-analyses we will discriminate between A and B/C as clinically relevant complications. We added this to the "Statistical analysis" section.
Question 1.7: General remark, only during the reading of the manuscript it becomes fully clear that this actual map has not been created yet. Would emphasize this better in abstract/ introduction. (minor) Answer 1.7: We completely agree that this is not clear at the moment and now mention this explicitly in the abstract: "After completion of the project, a permanently updated evidence map of pancreatic surgery will be available to patients, physicians, researchers and funding bodies via www.evidencemap.surgery." Question 1.8: Methods, would provide time frames in more detail. For instance, on when the first version is expected and when updates (how many times per year) will be done. Finally, it may be realistic to present this work for the coming x (say, 5?) years. As it stands now, it is a non-ending "pledge" to update this website. It may be reasonable to reflect after a certain number of years.
(major) Answer 1.8: We agree that this information would be important to share. Therefore, we formulated this in a detailed time frame given in the discussion section of the manuscript: "The first version will be presented at the World Pancreas Forum (Bern, Switzerland; www.worldpancreasforum.com) on February 6th 2020. The first citable version i.e. a version of which cornerstone data will be published in a peer-reviewed journal is planned for the end of 2020. After this the online version will be updated every 6 months and a new citable version is planned after 2 and 4 years. Thereafter, the impact on literature and research of the evidence map will be re-evaluated."
Reviewer #2: Chris Marshall, Newcastle University, UK Question 2.1: I wonder if the authors could provide some justification for the limtied selection of resources they have chosen to search. Are there not, for example, any specialised conferences that would be of interest to search for evidence here? Answer 2.1: Thank you for asking about our strategy of resources and we are aware of the ongoing discussion whether congress abstracts are a valid source of information in systematic reviews. One of the aims of the evidence map was to focus on high-quality data from RCT and we think it would be counterproductive to open the sources for unpublished/ unreviewed data. However, we agree that with actual version there is the possibility of missing recent developments and therefore we decided to include also published protocols for RCT about pancreatic surgery. Under the section "Data synthesis for creation of the evidence map" it now says: "Protocols of ongoing RCT will be displayed within the evidence map until the final results are available." Question 2.2: I see there are some preliminary scoping search numbers reported in the Dissemination section, but I suggest placing these in the earlier sections relating to the search. Answer 2.2: We completely agree and moved this information from the "Dissemination" section to the "Systematic literature search" section.
Question 2.3: Please can the authors provide clarification on the study selection process? For example, how will any conflicts/disagreements between the independent reviewers be resolved? Will you be using any specialised software to carry out the screening? Answer 2.3: Thank you for asking for more detailed information on this important part. If there is a disagreement between the two reviewers, this will be resolved by a third reviewer. We will perform the screening process with a separate EndNote file for each of the two reviewers. No special software will be used at this stage. We added this to the "Study selection" section: "If there is a disagreement between the two reviewers, this will be resolved by a third reviewer. The screening process will be done with the bibliographic software EndNote X9 (Clarivate Analytics)."
Question 2.4: Are the 'minimal requirements' for an SR you set out based on any established quality criteria for an SR (e.g. ROBIS)? Answer 2.4: The minimal requirements to include an SR into the evidence map are based on the Cochrane Handbook recommending searching at least two different databases and to perform critical appraisal with a validated tool. Please see also our answer to your question 2.6.
Question 2.5: I think it would be useful for clarity to see a PICO Question 2.6: Are you formally critically appraising the included SRs as well as the RCTs? Answer 2.6: There will be no critical appraisal of the included systematic reviews. The only reason to include the systematic reviews in the map is the detection of research gaps defined by missing RCT. We think that a critical appraisal e.g. by AMSTAR, would not substantially contribute to this purpose and would also mean a large additional, however, unjustified workload.
Question 2.7: Regarding the data extraction, you mention a pre-defined spreadsheet earlier in the protocol but then later on talk about a database 'tailored for this project' will be used to 'save resources during data extraction'. Are you extracting straight into this database or are you going to use the spreadsheet and then translate data into this database later? Please clarify. Answer 2.7: Thank you for pointing out this incongruence. We have pre-defined items which we will extract from studies and enter it directly in a specifically programmed user interface. The data will then be saved on the relational database. The user interface itself has a plausibility check function and reviewers' entries can be double checked. We added screenshots of the user interface instead of a table as appendix 2 and changed the "Data extraction" section: "All stages of data extraction and quality assessment will be carried out independently by two reviewers using predefined items. Any disagreement will be resolved by consensus, or by consultation with a third reviewer. The items are directly extracted to a user interface (Microsoft .NET framework, Windows Forms) with automated plausibility checks. The data will be saved in a database (Microsoft SQL Server 2017 Express) tailored for this project. The database will allow saving resources during data extraction and making data usable for presentation on the evidence map and for statistical analysis. After validation of the extracted data, the relational database will be able to export the extracted data in the exact form needed for presentation on the evidence map. Further, the database will have an interface to the statistical program to export data needed for the meta-analyses. All extracted items for RCT and SR within the user interface are shown in appendix 2."
